8-K: Current report filing
Published on February 15, 2007
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 8, 2007
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
/ / Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
/ / Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
/ / Pre-commencement communications pursuant to Rule 13e-4(c)) under the
Exchange Act (17 CFR 240.13e-4 (c))
Item 5.02
Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
- ------------------------------------------------------------------------
Effective February 8, 2007, the Board of Directors of Access
Pharmaceuticals, Inc. (the "Company") elected Estaban Cvitkovik, MD
as a member of the Company's Board of Directors. Dr. Cvitkovik also
assumed the title of Vice Chairman (Europe) as of that date.
Dr. Cvitkovik is currently a Senior Medical Consultant to AAIOncology,
an oncology focused CRO based in France. Recently, the oncology focused
CRO Cvitkovic & Associes Consultants, founded by Dr. Cvitkovic
11 years ago, was sold to AAIPharma to become AAIOncology. In addition,
he maintains a part-time academic practice including teaching at the
Beaujon and St. Louis hospitals in Paris. Dr. Cvitkovic is also
Scientific President of the FNAB, a foundation devoted to the
furthering of personalized cancer treatments. Together with a small
number of collaborators he recently co-founded Oncoethix, a biotech
company focused on licensing and co-development of anti-cancer
molecules. Dr. Cvitkovic has also held staff and academic
appointments at Memorial Sloan Kettering Cancer Center (New York),
Columbia Presbyterian (New York), Instituto Mario Negri (Milan),
Institute Gustave Roussy (Villejuif), and Hopital Paul St. Louis
(Paris).
Effective February 8, 2007, Stuart M. Duty resigned from the Board of
Directors.
Item 9.01
Financial Statements and Exhibits
- ---------------------------------
A press release is attached as Exhibit 99.1 to this report and is
Incorporated herein by this reference, in which the Company announced
its new director Estaban Cvitkovik, MD.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Access Pharmaceuticals, Inc.
(Registrant)
By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer
Dated February 15, 2007
3